Sarepta says it has what could be the first gene therapy for limb girdle muscular dystrophy. But approval is going to be ...
By grounding himself in the reasons why he keeps moving forward, columnist Patrick Moeschen is able to figure out how to ...
Stocktwits on MSN
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket
Shares of Sarepta Therapeutics rose nearly 5% in early premarket trading on Wednesday as the company prepared to present new ...
– U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5 – Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3 – Data expected for SRP-9003 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback